Germline-activating mutations in PIK3CD compromise B cell development and function.
Germline-activating mutations in PIK3CD compromise B cell development and function.
复制标题
DOI:
10.1084/jem.20180010
复制
发表时间:
2018-08-06
期刊:
影响因子:
--
通讯作者:
Tangye SG
中科院分区:
文献类型:
--
作者:
Avery DT;Kane A;Nguyen T;Lau A;Nguyen A;Lenthall H;Payne K;Shi W;Brigden H;French E;Bier J;Hermes JR;Zahra D;Sewell WA;Butt D;Elliott M;Boztug K;Meyts I;Choo S;Hsu P;Wong M;Berglund LJ;Gray P;O'Sullivan M;Cole T;Holland SM;Ma CS;Burkhart C;Corcoran LM;Phan TG;Brink R;Uzel G;Deenick EK;Tangye SG
PIK3CD mutations cause immune dysregulation. By studying humans and a novel mouse model, we show these mutations intrinsically impair B-cell development and function. These findings reveal mechanisms of compromised humoral immunity due to PIK3CD mutations, and opportunities to pharmacologically restore these defects. Gain-of-function (GOF) mutations in PIK3CD, encoding the p110δ subunit of phosphatidylinositide 3-kinase (PI3K), cause a primary immunodeficiency. Affected individuals display impaired humoral immune responses following infection or immunization. To establish mechanisms underlying these immune defects, we studied a large cohort of patients with PIK3CD GOF mutations and established a novel mouse model using CRISPR/Cas9-mediated gene editing to introduce a common pathogenic mutation in Pik3cd. In both species, hyperactive PI3K severely affected B cell development and differentiation in the bone marrow and the periphery. Furthermore, PI3K GOF B cells exhibited intrinsic defects in class-switch recombination (CSR) due to impaired induction of activation-induced cytidine deaminase (AID) and failure to acquire a plasmablast gene signature and phenotype. Importantly, defects in CSR, AID expression, and Ig secretion were restored by leniolisib, a specific p110δ inhibitor. Our findings reveal key roles for balanced PI3K signaling in B cell development and long-lived humoral immunity and memory and establish the validity of treating affected individuals with p110δ inhibitors.
登录
查看更多内容
影响因子:
30.5
作者:
通讯作者:
--
影响因子:
4.4
作者:
Andjelic, S;Hsia, C;Liou, HC
通讯作者:
Liou, HC
DOI:
10.1016/j.jaci.2016.06.021
发表时间:
2017-02
期刊:
The Journal of allergy and clinical immunology
影响因子:
--
作者:
Coulter TI;Chandra A;Bacon CM;Babar J;Curtis J;Screaton N;Goodlad JR;Farmer G;Steele CL;Leahy TR;Doffinger R;Baxendale H;Bernatoniene J;Edgar JD;Longhurst HJ;Ehl S;Speckmann C;Grimbacher B;Sediva A;Milota T;Faust SN;Williams AP;Hayman G;Kucuk ZY;Hague R;French P;Brooker R;Forsyth P;Herriot R;Cancrini C;Palma P;Ariganello P;Conlon N;Feighery C;Gavin PJ;Jones A;Imai K;Ibrahim MA;Markelj G;Abinun M;Rieux-Laucat F;Latour S;Pellier I;Fischer A;Touzot F;Casanova JL;Durandy A;Burns SO;Savic S;Kumararatne DS;Moshous D;Kracker S;Vanhaesebroeck B;Okkenhaug K;Picard C;Nejentsev S;Condliffe AM;Cant AJ
通讯作者:
Cant AJ
DOI:
10.1126/science.1243292
发表时间:
2013-11-15
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Angulo I;Vadas O;Garçon F;Banham-Hall E;Plagnol V;Leahy TR;Baxendale H;Coulter T;Curtis J;Wu C;Blake-Palmer K;Perisic O;Smyth D;Maes M;Fiddler C;Juss J;Cilliers D;Markelj G;Chandra A;Farmer G;Kielkowska A;Clark J;Kracker S;Debré M;Picard C;Pellier I;Jabado N;Morris JA;Barcenas-Morales G;Fischer A;Stephens L;Hawkins P;Barrett JC;Abinun M;Clatworthy M;Durandy A;Doffinger R;Chilvers ER;Cant AJ;Kumararatne D;Okkenhaug K;Williams RL;Condliffe A;Nejentsev S
通讯作者:
Nejentsev S
影响因子:
5.4
作者:
Agematsu, K;Nagumo, H;Komiyama, A
通讯作者:
Komiyama, A